Neuraxpharm Snapped Up By Private Equity In Europe’s Largest Deal
Under Control Of Apax Partners Since 2016
Created in 2016 by consolidating five European companies, CNS specialist Neuraxpharm is changing hands, with funds advised by global investor Permira paying an undisclosed sum to take control of a business boasting annual revenues of around €460m ($541m) and more than 115 CNS molecules at its disposal.
You may also be interested in...
Neuraxpharm Recruits Another Viatris Executive To Lead European Expansion
For the second time in as many months, Neuraxpharm has looked to Viatris to recruit a top executive to help lead the CNS specialist’s continuing expansion in Europe.
Neuraxpharm Expands Into The Nordics With New Leader From Viatris
In line with its plan to expand into the Nordics, CNS specialist Neuraxpharm has established a new business unit in Stockholm and has recruited Viatris’ Magnus Wassén to lead it as general manager. The company is expecting Neuraxpharm Sweden to provide an immediate sales platform for Buccolam.
Neuraxpharm CEO Confirms Expansion Into New Markets, Including US
In an exclusive interview with Generics Bulletin, Neuraxpharm CEO Jörg-Thomas Dierks reveals that the company plans to expand out of Europe into other markets by acquiring companies in regions such as the US.